Atlas Trials

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical trial NCT02014558 · COMPLETED

Trial details

NCT number
NCT02014558
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2013-10-09
Primary completion
2017-08-04
Enrollment
265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.